33 results
20-F/A
2023 FY
CYTO
Altamira Therapeutics Ltd
22 Apr 24
Annual report (foreign) (amended)
4:31pm
expert
ITEM 16B. Code of ethics
ITEM 16C. Principal Accountant Fees and Services
ITEM 16D. Exemptions from the listing standards for audit committees
ITEM … is defined by the SEC, and is independent for the purposes of SEC and Nasdaq rules.
ITEM 16B. Code of ethics
Code of Business Conduct and Ethics
We have
6-K
EX-99.3
CYTO
Altamira Therapeutics Ltd
8 Sep 21
Current Report of Private Issuer
9:01am
and treatment of acute COVID-19. The study is pending approval by the Drugs Controller General of India and local ethics committees.
In order to help ensure
6-K
EX-99.1
lp9324ebgzyw1 ssti6
14 Mar 19
Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
7:02am
424B3
8h6f4 pxd2ass
20 Feb 19
Prospectus supplement
5:01pm
F-1/A
ooanj27x4y
13 Feb 19
Registration statement (foreign) (amended)
5:21pm
F-1
mpjxgejscpjpyks
1 Feb 19
Registration statement (foreign)
8:01am
424B5
4wnk40rjixrj7ze12t
13 Dec 18
Prospectus supplement for primary offering
8:28am
424B5
8i9ohefdw1
30 Nov 18
Prospectus supplement for primary offering
9:01am
424B5
snyd10vdrpm 6p135
29 Nov 18
Prospectus supplement for primary offering
8:27am
424B3
fshkztqqsyg0r fa0
29 Nov 18
Prospectus supplement
8:19am
F-3
01tj8uze5noyu0fxfmqz
1 Nov 18
Shelf registration (foreign)
4:50pm
424B4
ep2 3swvvzfzld36u1
16 Jul 18
Prospectus supplement with pricing info
4:40pm
F-1/A
vnv47 drd3
12 Jul 18
Registration statement (foreign) (amended)
6:18am
F-1/A
6m8ch3w07n
2 Jul 18
Registration statement (foreign) (amended)
9:59pm